Netherlands Archives

Latest Posts

Scenic Biotech Genetic Off Switch Cancer Rare Disease

News and Trends 5 Jun 2017

New Dutch Biotech Gets Funding to Find Genetic Off Switches

Scenic Biotech is applying a technology to identify first-in-class therapeutic targets that has secured it €6.5M in Series A. Scenic Biotech, founded in Amsterdam just this year, has raised €6.5M to…

June 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of…

May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

Interview 8 May 2017

Meet the co-developer of the first commercial mAb and gene therapy

Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene…

May 8, 2017 - 5 minutesmins - By Philip Hemme

Startup Scout 28 Apr 2017

This Dutch Biotech Could Boost Gene Editing of Primary Cells

Located in the charming town of Utrecht in the Netherlands, Ntrans Technologies was newly founded in 2015 based on a cutting-edge intracellular delivery technology developed at the Hubrecht Institute of the Royal Netherlands Academy…

April 28, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 26 Apr 2017

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis' MAA with the EMA doesn't come as…

April 26, 2017 - 1 minutemin - By Melanie De Almeida

News and Trends 25 Apr 2017

EMA designates uniQure’s gene therapy for hemophilia a priority

Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial…

April 25, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 20 Apr 2017

Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn

The excitement about the therapy was undercut when it became clear Glybera would be a commercial failure. In October, it will officially be dead. uniQure has announced that it will not go…

April 20, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 14 Mar 2017

Huge Successful €103M IPO for the Next European Leader in Bioplastics

Avantium has gone public and raised €103M on Euronext Amsterdam and Euronext Bruxelles with Sofinnova Partner as the main shareholder. Avantium, a spin-off from Shell, is developing renewable bioplastics made…

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

argenx llama antibody immuno oncology IPO

News and Trends 22 May 2017

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial…

May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

cultured meat market 2020 1 e1488366878713

More News! 1 Mar 2017

Lab-Grown Meat Could Hit the Market as Soon as 2020

Cultured meat could be a sustainable, healthy and inexpensive food alternative in a future that might be closer than we think. We recently attended the 2nd International Conference on Cultured Meat,…

March 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 May 2017

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II…

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Arthrogen rheumatoid arthritis gene therapy

News and Trends 17 Feb 2017

Gene Therapy for Rheumatoid Arthritis gets Approval to Start Clinical Trials

Arthrogen will start a Phase Ib trial for a gene therapy aiming to treat rheumatoid arthritis with a single injection and reduce costs for patients. Arthrogen, based in Amsterdam, is developing…

February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering